Skip to main content
Publications
Anthony MS, Djebarri L, Beachler DC, Aroda VR, Calingaert B, Pan C, Crowe C, Lanes S, Rothman KJ, Saltus CW, Berreghis S, Parlett LE, Bocage C, Walsh KE, Juhaeri J, Johannes C. Risk of anaphylaxis among new users of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Poster presented at the American Diabetes Association's 83rd Scientific Sessions; June 23, 2023. San Diego, CA. [abstract] Diabetes. 2023 Jun 20; 72(supplement_1):846-P. doi: 10.2337/db23-846-P
Dong OM, Roberts MC, Wu RR, Voils CI, Sperber N, Gavin KL, Bates J, Chanfreau-Coffinier C, Naglich M, Kelley MJ, Vassy JL, Sriram P, Heise CW, Rivas S, Ribeiro M, Chapman JG, Voora D. Evaluation of the veterans affairs pharmacogenomic testing for veterans (PHASER) clinical program at initial test sites. Pharmacogenomics. 2021 Nov 1;22(17):1121-33. doi: 10.2217/pgs-2021-0089
Dong OM, Bates J, Chanfreau-Coffinier C, Naglich M, Kelley MJ, Meyer LJ, Icardi M, Vassy JL, Sriram P, Heise CW, Rivas S, Ribeiro M, Jacobitz R, Rozelle S, Chapman JG, Voora D. Institutional profile: veterans affairs pharmacogenomic testing for veterans (PHASER) program. Pharmacogenomics. 2021 Jan 6;22(3):2020-0173. doi: 10.2217/pgs-2020-0173
Nance RM, Vannappagari V, Smith K, Johannes CB, Calingaert B, Saltus CW, Mayer KH, Whitney BM, Rodriguez B, Moore RD, Eron JJ, Geng E, Mathews WC, Mugavero MJ, Saag MS, Kitahata MM, Delaney JAC, Crane HM. Virologic failure among people living with HIV initiating dolutegravir-based versus other recommended regimens in real-world clinical care settings. J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):572-7. doi: 10.1097/QAI.0000000000002075
Perez L, Medina-Ramon M, Kunzli N, Alastuey A, Pey J, Perez N, Garcia R, Tobias A, Querol X, Sunyer J. Size fractionate particulate matter, vehicle traffic, and case-specific daily mortality in Barcelona, Spain. Environ Sci Technol. 2009 Jul 1;43(13):4707-14. doi: 10.1021/es8031488